Navigation Links
InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
Date:7/13/2009

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Geoffrey M. Parker has joined InteKrin as Chief Business Officer. Most recently, Mr. Parker served as a Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. Over the past ten years, Mr. Parker led Goldman Sachs' West Region Healthcare Investment Banking practice during which time he advised many of the biotechnology industry's leading companies.

"We are very pleased to have such an eminent healthcare business professional join us," said Denny Lanfear, InteKrin Chief Executive. "The expertise, insights and depth of business experience Geoff brings are complementary to the InteKrin team's capabilities as world class drug developers and scientists."

"InteKrin is an exciting opportunity and INT131 presents significant promise for patient benefit," said Geoff. "INT131 has the potential to be a breakthrough product, and I am delighted to be part of the InteKrin team as we complete our Phase 2 work and plan to advance into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity
'/>"/>

SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. InteKrin Therapeutics Announces $20 Million Series C Financing
3. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... detection methods that can rapidly screen a large ... cell inside that population has been seriously lacking," ... In the Royal Society of Chemistry journal ... and his coworkers have developed a novel technique ... ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... and vegetables are often displayed in the popular ... also plenty of high-sugar foods. A new study ... is portrayed in children,s TV programmes as well ... dietary habits and weight status. , Steingerdur Olafsdottir,s ... in the popular Swedish children,s TV show Bolibompa. ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... abstract that will be presented on Wednesday at SLEEP ... Sleep Societies (APSS), finds a link between normal sleep ... Ancoli-Israel, PhD, of the University of California at San ... of age or older. Reports of use of ...
... 11 DaVita Inc., a leading,provider of kidney ... and disease (CKD), recently announced that Debbie Benner, ... DaVita(R) and Mary,Burgess, RD, Grant Program Manager for ... abstracts at the XIV International Congress on,Nutrition and ...
... first time, UCLA researchers have discovered that people with ... help store memory. Reported in the June 27 edition ... importance of early detection of the disorder, which afflicts ... Sleep apnea occurs when a blocked airway repeatedly halts ...
... nonprofit organization, has announced it is offering free,step-by-step assistance to uninsured ... its mission to improve the overall,health of Americans throughout the United ... sites or,calling its toll-free numbers:, -- For English: ... ...
... SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- Fresenius Medical ... in the Chinese,province of Sichuan. In addition to ... of $1.1 million in both cash and material ... by the natural disaster.,Fresenius Medical Care is providing ...
... workers revive unconscious passenger, SACRAMENTO, Calif., June ... saved the life of a 53-year-old,passenger on their ... The trio was among a group of ... to attend a contract bargaining session with their,employer, ...
Cached Medicine News:Health News:Normal sleep linked to successful aging 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2Health News:Memory loss linked to common sleep disorder 2Health News:Memory loss linked to common sleep disorder 3Health News:The CoverMe Foundation Offers Free, Step-By-Step Assistance to Connect Uninsured with Free or Reduced-Cost Health Care 2Health News:Fresenius Medical Care Supports Chinese Earthquake Victims 2Health News:UHW Members Save Man's Life On Flight 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 1 Graymark Healthcare , Inc. (Nasdaq: ... which Walgreen Co. will acquire substantially all of the ... Graymark Healthcare . Graymark expects to realize a total ... AR, expenses and proceeds from the liquidation of remaining ...
... Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company 2Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 2French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 4French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 5French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 6French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 7
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... Ureteral Access Sheath, you can have all ... - plus an entirely new level of ... designed with a proprietary dual lumen design, ... channel for a variety of procedural steps ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
Medicine Products: